BRPI0719092B8 - compostos do tipo tetra-hidrociclopen-ta[b]indol, seus usos, e composição farmacêutica - Google Patents

compostos do tipo tetra-hidrociclopen-ta[b]indol, seus usos, e composição farmacêutica

Info

Publication number
BRPI0719092B8
BRPI0719092B8 BRPI0719092A BRPI0719092A BRPI0719092B8 BR PI0719092 B8 BRPI0719092 B8 BR PI0719092B8 BR PI0719092 A BRPI0719092 A BR PI0719092A BR PI0719092 A BRPI0719092 A BR PI0719092A BR PI0719092 B8 BRPI0719092 B8 BR PI0719092B8
Authority
BR
Brazil
Prior art keywords
type compounds
compound
formula
tetrahydrocyclopen
pharmaceutical composition
Prior art date
Application number
BRPI0719092A
Other languages
English (en)
Inventor
Paul Matthews Donald
Edward Green Jonathan
Gavardinas Konstantinos
Kondaji Jadhav Prabhakar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0719092A2 publication Critical patent/BRPI0719092A2/pt
Publication of BRPI0719092B1 publication Critical patent/BRPI0719092B1/pt
Publication of BRPI0719092B8 publication Critical patent/BRPI0719092B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

compostos do tipo tetra-hidrociclopenta[b]indol como moduladores de receptores de androgênio. a presente invenção refere-se a um composto da fórmula: ou um sal farmaceuticamente aceitável do mesmo; composições farmacêuticas compreendendo um composto de fórmula (i) em combinação com um veículo, diluente, ou excipiente adequado; e métodos para o tratamento de distúrbios fisiológicos, particularmente massa óssea reduzida, osteoporose, osteopenia, ou massa ou força muscular reduzida, que compreende administrar um composto de fórmula (i), ou um sal farmaceuticamente aceitável do mesmo.
BRPI0719092A 2006-11-20 2007-11-06 compostos do tipo tetra-hidrociclopen-ta[b]indol, seus usos, e composição farmacêutica BRPI0719092B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20
US60/866,484 2006-11-20
PCT/US2007/083745 WO2008063867A2 (en) 2006-11-20 2007-11-06 Tetrahydrocyclopenta[b] indole compounds as androgen receptor modulators

Publications (3)

Publication Number Publication Date
BRPI0719092A2 BRPI0719092A2 (pt) 2013-12-03
BRPI0719092B1 BRPI0719092B1 (pt) 2020-08-18
BRPI0719092B8 true BRPI0719092B8 (pt) 2021-05-25

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719092A BRPI0719092B8 (pt) 2006-11-20 2007-11-06 compostos do tipo tetra-hidrociclopen-ta[b]indol, seus usos, e composição farmacêutica

Country Status (37)

Country Link
US (1) US7968587B2 (pt)
EP (1) EP2094658B1 (pt)
JP (1) JP5399259B2 (pt)
KR (1) KR101121471B1 (pt)
CN (1) CN101541749B (pt)
AR (1) AR063559A1 (pt)
AT (1) ATE538091T1 (pt)
AU (1) AU2007324046B2 (pt)
BR (1) BRPI0719092B8 (pt)
CA (1) CA2670340C (pt)
CL (1) CL2007003182A1 (pt)
CO (1) CO6190513A2 (pt)
CR (1) CR10802A (pt)
CY (1) CY1112284T1 (pt)
DK (1) DK2094658T3 (pt)
EA (1) EA015627B1 (pt)
EC (1) ECSP099350A (pt)
ES (1) ES2376048T3 (pt)
HK (1) HK1134089A1 (pt)
HR (1) HRP20120032T1 (pt)
IL (1) IL198410A (pt)
JO (1) JO2800B1 (pt)
MA (1) MA31072B1 (pt)
MX (1) MX2009005251A (pt)
MY (1) MY154547A (pt)
NO (1) NO342531B1 (pt)
NZ (1) NZ576296A (pt)
PE (1) PE20081161A1 (pt)
PL (1) PL2094658T3 (pt)
PT (1) PT2094658E (pt)
RS (1) RS52191B (pt)
SI (1) SI2094658T1 (pt)
TN (1) TN2009000189A1 (pt)
TW (1) TWI398438B (pt)
UA (1) UA98777C2 (pt)
WO (1) WO2008063867A2 (pt)
ZA (1) ZA200903096B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
CA2724629C (en) * 2008-05-16 2014-08-19 Eli Lilly And Company Tetrahydrocyclopenta[b]indole androgen receptor modulators
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
EP3106159A1 (en) 2010-05-12 2016-12-21 Radius Health, Inc. Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
WO2012152741A1 (de) 2011-05-10 2012-11-15 Bayer Intellectual Property Gmbh Bicyclische (thio)carbonylamidine
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
RU2022108295A (ru) 2016-06-22 2022-04-06 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
KR102557321B1 (ko) 2017-01-05 2023-07-18 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
EP3817821A1 (en) 2018-07-04 2021-05-12 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
JP2023511612A (ja) * 2020-01-27 2023-03-20 エイルゲン ファーマ リミテッド 腎臓疾患の治療のためのテトラヒドロシクロペンタ［ｂ］インドール化合物
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) * 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) * 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) * 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) * 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE60032780T2 (de) * 1999-10-14 2007-11-08 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinolin-derivate
US7160909B2 (en) 2001-08-09 2007-01-09 Eli Lilly And Company Cyclopenta[b]indole derivatives as sPLA2 inhibitors
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
AU2003231509A1 (en) * 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
WO2005092854A1 (en) * 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
EP1817026A2 (en) * 2004-11-22 2007-08-15 SmithKline Beecham Corporation Hcv inhibitors
CA2588389A1 (en) 2004-11-23 2006-06-22 Ptc Therapeutics, Inc. Substituted phenols as active agents inhibiting vegf production
MX2007009783A (es) 2005-02-17 2007-08-22 Wyeth Corp Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilfusionados.
EP1902026B1 (en) 2005-06-24 2010-02-17 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
CA2724629C (en) 2008-05-16 2014-08-19 Eli Lilly And Company Tetrahydrocyclopenta[b]indole androgen receptor modulators

Also Published As

Publication number Publication date
CA2670340C (en) 2014-05-20
ECSP099350A (es) 2009-06-30
CN101541749A (zh) 2009-09-23
NO342531B1 (no) 2018-06-11
CO6190513A2 (es) 2010-08-19
HK1134089A1 (en) 2010-04-16
BRPI0719092B1 (pt) 2020-08-18
SI2094658T1 (sl) 2012-04-30
BRPI0719092A2 (pt) 2013-12-03
NZ576296A (en) 2011-11-25
TN2009000189A1 (en) 2010-10-18
EP2094658B1 (en) 2011-12-21
KR20090082229A (ko) 2009-07-29
CN101541749B (zh) 2013-03-27
EA200970500A1 (ru) 2009-10-30
IL198410A (en) 2013-09-30
MA31072B1 (fr) 2010-01-04
PT2094658E (pt) 2012-02-22
PE20081161A1 (es) 2008-08-15
TWI398438B (zh) 2013-06-11
WO2008063867A2 (en) 2008-05-29
CA2670340A1 (en) 2008-05-29
JO2800B1 (en) 2014-03-15
EP2094658A2 (en) 2009-09-02
WO2008063867A3 (en) 2008-07-31
ATE538091T1 (de) 2012-01-15
EA015627B1 (ru) 2011-10-31
TW200827347A (en) 2008-07-01
MY154547A (en) 2015-06-30
MX2009005251A (es) 2009-08-19
CL2007003182A1 (es) 2008-06-27
US7968587B2 (en) 2011-06-28
AU2007324046A1 (en) 2008-05-29
DK2094658T3 (da) 2012-02-13
ZA200903096B (en) 2010-07-28
RS52191B (en) 2012-10-31
NO20092103L (no) 2009-05-28
AR063559A1 (es) 2009-02-04
US20100069404A1 (en) 2010-03-18
AU2007324046B2 (en) 2012-04-05
HRP20120032T1 (hr) 2012-02-29
JP2010510231A (ja) 2010-04-02
KR101121471B1 (ko) 2012-02-28
UA98777C2 (en) 2012-06-25
JP5399259B2 (ja) 2014-01-29
CR10802A (es) 2009-07-13
IL198410A0 (en) 2010-02-17
PL2094658T3 (pl) 2012-05-31
CY1112284T1 (el) 2015-12-09
ES2376048T3 (es) 2012-03-08

Similar Documents

Publication Publication Date Title
BRPI0719092B8 (pt) compostos do tipo tetra-hidrociclopen-ta[b]indol, seus usos, e composição farmacêutica
BRPI0508820B8 (pt) compostos moduladores de receptor de opióide e composição que os compreende
EA201071317A1 (ru) ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ
ATE457979T1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
ATE412647T1 (de) Substituierte n-arylpyrrolidine als selektive modulatoren des androgenrezeptors
BRPI1013579A2 (pt) derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos
MX2009013989A (es) Terapia en combinacion para depresion.
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
MY149731A (en) Compounds
MX363023B (es) Formulaciones orales de analogos de citidina y metodos para usar los mismos.
CO6270360A2 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
BR112012019551A2 (pt) moduladores seletivos do receptor de androgênio.
EA201290394A1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
GB0722077D0 (en) Compounds
BR112013025128A2 (pt) derivados de pirrol como moduladores de receptor de acetilcolina nicotínico para uso no tratamento de distúrbios neurodegenenerativos tal como doença de alzheimer e doença de parkinson
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BR112013000164A2 (pt) agente terapêutico ou agente profilático
IL206611A0 (en) Novel imidazolinylmethyl aryl sulfonamides
IL195969A0 (en) Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition
DOP2009000117A (es) Compuestos de tetrahidrociclopenta[b]indol como moduladores del receptor de andrógenos
UA97374C2 (ru) Производные азаиндола с комбинацией частичного агонизма к никотиновому ацетилхолиновому рецептору и ингибирование обратного захвата допамина
WO2009018367A3 (en) Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine
UY31030A1 (es) Compuestos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/11/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF